

Instance: composition-en-96431077feaab94e628cf99788cf8afd
InstanceOf: CompositionUvEpi
Title: "Composition for vazkepa Package Leaflet"
Description:  "Composition for vazkepa Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vazkepa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet </p>
<ol>
<li>What Vazkepa is and what it is used for </li>
<li>What you need to know before you take Vazkepa </li>
<li>How to take Vazkepa </li>
<li>Possible side effects </li>
<li>How to store Vazkepa </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vazkepa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vazkepa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vazkepa contains the active substance icosapent ethyl, a highly purified omega-3 fatty acid from fish 
oil.  </p>
<p>Vazkepa lowers levels of triglycerides (types of fat) in the blood and it is used with a statin medicine 
(that lowers blood cholesterol) to prevent cardiovascular events, such as:</p>
<ul>
<li>heart attack </li>
<li>stroke </li>
<li>death from heart or vascular disease </li>
</ul>
<p>Vazkepa is used in adults with high blood triglycerides who already have heart disease or have 
diabetes and other conditions that put them at a higher risk of cardiovascular events. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vazkepa<br />
- If you are allergic to icosapent ethyl, soya or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Vazkepa:</p>
<ul>
<li>If you are allergic to fish or to shellfish. </li>
<li>If you have problems with your liver. </li>
<li>If you have problems with irregular heartbeat (atrial fibrillation or flutter). </li>
<li>If you take an anticoagulant medicine (which prevents blood from clotting), medicines that 
inhibit platelets in the blood or are at risk of bleeding. </li>
</ul>
<p>If any of the above applies to you, talk to your doctor. </p>
<p>Blood tests 
During your treatment your doctor may carry out blood tests to check for any problems with your liver 
and to check how your blood is clotting. </p>
<p>Children and adolescents 
Do not give this medicine to children and young people below 18 years of age because it has not been 
studied in these people. </p>
<p>Other medicines and Vazkepa 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>If you are taking other medicines at the same time as Vazkepa that affect how your blood clots, such 
as an anticoagulant medicine, you will have blood tests during treatment. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy 
Vazkepa is not recommended for use during pregnancy unless your doctor advises you to take it. </p>
<p>Breast-feeding 
Vazkepa is not recommended for use while breast-feeding as the effect on your baby is not known. 
Your doctor will help you to weigh up the benefit of treatment against any risk to your breast-feeding 
baby. </p>
<p>Fertility 
Talk with your doctor about fertility during treatment. </p>
<p>Driving and using machines 
This medicine is unlikely to affect your ability to drive or use tools or machines. </p>
<p>Vazkepa contains maltitol, sorbitol and soya lecithin  </p>
<p>Maltitol (E965 ii) 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>Sorbitol (E420 ii) 
This medicine contains 83 mg sorbitol in each capsule. </p>
<p>Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars 
or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in 
which a person cannot break down fructose, talk to your doctor before you take this medicine. </p>
<p>Soya lecithin 
This medicine contains soya lecithin. If you are allergic to soya or peanut, do not use this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. Do not change your dose without talking to your doctor. </p>
<p>How to open bottle 
Push down the screw cap and turn it anticlockwise.  </p>
<p>How much to take 
The recommended dose is two capsules by mouth, twice a day, with or after a meal. </p>
<p>Swallow the capsules whole; Do not break, crush, dissolve or chew the capsules. </p>
<p>Use in elderly 
There is no need to change the dose in elderly patients. They can take the usual recommended dose. </p>
<p>If you take more Vazkepa than you should 
If you accidentally take more capsules than your doctor has prescribed, contact your doctor or 
pharmacist for advice. </p>
<p>If you forget to take Vazkepa 
If you miss a dose, take it as soon as you remember. However if you missed taking the medicine for a 
whole day, just take your next scheduled dose. Do not take a double dose to make up for a forgotten 
dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>
<p>If you stop taking Vazkepa 
Do not stop taking this medicine until you have spoken with your doctor. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact your doctor 
* if you get heart palpitations or irregular heartbeat. These could be symptoms of a serious 
condition known as atrial fibrillation. This is a common side effect (may affect up to 
1 in 10 people): 
* if you bruise easily or cannot stop bleeding. This is a very common side effect (may affect more 
than 1 in 10 people). Your risk of bleeding may increase if you are also taking an anticoagulant 
medicine.  </p>
<p>Get medical help if you get any of the following side effects. These symptoms could be due to a 
serious condition known as hypersensitivity which can happen at any time during treatment. This is 
an uncommon side effect (may affect up to 1 in 100 people) 
* difficulty breathing 
* tightening or scratching of the throat 
* swelling of the lips 
* hives (raised bumps on the skin) 
* rash and an itchy skin 
* stomach pain or cramps 
* diarrhoea 
* nausea and vomiting 
Other side effects that may occur </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* swelling of your hands, arms, legs and feet<br />
* pain in muscles, bones or joints 
* gout (painful swelling in the joints because of a build up of uric acid) 
* rash 
* constipation 
* burping </p>
<p>Uncommon side effect (may affect up to 1 in 100 people) 
* bad taste in the mouth </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vazkepa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vazkepa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle label or blister carton after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Store below 30  C. </p>
<p>Bottle: keep the bottle tightly closed in order to protect from moisture. 
Blister pack: store in the original package in order to protect from moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vazkepa contains 
* The active substance is icosapent ethyl. Each Vazkepa capsule contains 998 mg of icosapent 
ethyl. 
* The other ingredients are  * all-rac-alpha-tocopherol, gelatin, glycerol, liquid maltitol (E965 ii), liquid sorbitol (non-
crystallising) (E420 ii), purified water and soya lecithin (see section 2  Vazkepa contains 
maltitol, sorbitol and soya lecithin ). * printing ink: titanium dioxide, propylene glycol, hypromellose. </p>
<p>What Vazkepa looks like and contents of the pack </p>
<p>In this pack you will find oblong soft capsules, 25 x 10 mm, printed with  IPE  in white ink, with a 
light yellow to amber shell containing a colourless to pale yellow liquid. </p>
<p>The bottles containing 120 capsules are white 300-cc, high density polyethylene (HDPE) with a child-
resistant polypropylene heat induction sealed closure. 
Pack size of one bottle or three bottles per carton. </p>
<p>The blister packs contain 4x2 capsules in PVC/PCTFE/Al perforated unit dose blisters. </p>
<p>Marketing Authorisation Holder 
Amarin Pharmaceuticals Ireland Limited<br />
88 Harcourt Street 
Dublin 2, D02DKIreland </p>
<p>Manufacturer 
MIAS Pharma Limited 
Suite 1, Stafford House, Strand Road 
Portmarnock,<br />
D13 WCIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Amarin Pharmaceuticals Ireland Limited 
T l/Tel: 0800-75AmarinConnect@amarincorp.eu </p>
<p>Lietuva 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited 
Te .: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Luxembourg/Luxemburg 
Amarin Pharmaceuticals Ireland Limited 
T l/Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>esk  republika 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Magyarorsz g 
Amarin Pharmaceuticals Ireland Limited 
Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Danmark 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Malta 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Deutschland 
Amarin Germany GmbH 
Tel: 0800-0008AmarinConnect@amarincorp.eu </p>
<p>Nederland 
Amarin Pharmaceuticals Ireland Limited 
Tel: 0800-0228AmarinConnect@amarincorp.eu </p>
<p>Eesti 
Amarin Pharmaceuticals Ireland Limited 
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Norge 
Amarin Pharmaceuticals Ireland Limited 
Tlf: +46 84 468 5AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited<br />
 : +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>sterreich 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 0800-281AmarinConnect@amarincorp.eu </p>
<p>Espa a 
Amarin Pharmaceuticals Ireland Limited<br />
Polska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 900806AmarinConnect@amarincorp.eu </p>
<p>Tel.: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>France 
Amarin Pharmaceuticals Ireland Limited<br />
T l: 0800-991AmarinConnect@amarincorp.eu </p>
<p>Portugal 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Hrvatska 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Rom nia 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Ireland 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Slovenija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>sland 
Amarin Pharmaceuticals Ireland Limited<br />
S mi: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Slovensk  republika 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Italia 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Suomi/Finland 
Amarin Pharmaceuticals Ireland Limited<br />
Puh/Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Amarin Pharmaceuticals Ireland Limited<br />
 : +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>Sverige 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +46-84-4685AmarinConnect@amarincorp.eu </p>
<p>Latvija 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: +353(0)16915AmarinConnect@amarincorp.eu </p>
<p>United Kingdom (Northern Ireland) 
Amarin Pharmaceuticals Ireland Limited<br />
Tel: 0800-0478AmarinConnect@amarincorp.eu </p>
<p>This leaflet was last revised in . </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

